• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • The Hatter Cardiovascular Institute Horizon Meetings
    • The 19th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2022 – London
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2022
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2022
    • Multiple Sclerosis Nurses at the Limits 2022
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Dr Kevin Franks

Kevin Franks (MBChB, MRCP, FRCR) is Consultant Clinical Oncologist at St James’s Institute of Oncology (SJIO), Leeds Cancer Centre, Leeds Teaching Hospital, UK.

Dr Franks trained as clinical oncologist in Leeds and completed a two-year clinical research fellow in lung technical radiotherapy at Princess Margaret Hospital under the supervision of Professor Andrea Bezjak and David Jaffray (2005-2007). He was appointed as consultant in Leeds in 2009 and as the clinical Lead for Lung Stereotactic Ablative Radiotherapy (SABR) he has established a large lung SABR program treating more than 700 patients since 2009.

In the UK, Dr Franks is a founding member of the UK SABR Consortium and is a member of the National Clinical Research Institute Clinical and Translational Radiotherapy Research Group (work stream 4). He was the co-chair of the National Cancer Action Team (NCAT) Image-guided Radiotherapy working group, which produced national guidelines on IGRT use in 2012 and is a member of the British Thoracic Society working group, which has produced guidelines for the investigation and management of pulmonary nodules (2013-2014).

Dr Franks’ research interests are in technical radiotherapy including 4DCT, SABR, image guided radiotherapy (IGRT), intensity + volume modulated radiotherapy (IMRT/VMAT) and radiotherapy informatics.

He is the principal investigator for the SABRtooth trial, a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing Stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of complications from surgical resection, which is due to start recruitment in early 2015.

In addition to SABRTooth, he is co-applicant on the ISOTOXIC IMRT CRUK funded UK study evaluating dose-escalated twice-daily intensity-modulated radiotherapy in locally advanced lung cancer: SARON – a CRUK funded study of SABR in addition to chemotherapy and conventional radiotherapy in patients presenting with curable local disease and small number oligometastases; and CORE – a CRUK study (initial phase accepted- full application submitted) of the role of SABR in patients that present with oligometases after curative treatment of breast, lung and prostate cancer.

« Professor Dmitri Lapotko
Professor Gerard Evan »

The 19th Malvern Diabetic Foot Conference
Wednesday, 11 - Friday, 13 May 2022, Malvern, UK

Cell Therapy at the Limits 2022
Monday, 27 & Tuesday, 28 June 2022, London, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 16 & Saturday, 17 September 2022, London, UK

Multiple Sclerosis at the Limits
Monday, 19 & Tuesday, 20 September 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits Japan
Saturday 15th & Sunday 16th October 2022, Tokyo, Japan

Cardiology, Diabetes & Nephrology at the Limits Canada
Q3 2022, Toronto, Canada

Cardiology, Diabetes & Nephrology at the Limits Brazil
April & October 2022, Brazil

The Hatter Cardiovascular Institute Horizon GP Meeting
Wednesday, 9 November 2022
London, UK

The Hatter Cardiovascular Institute Horizon Meeting
Wednesday, 23 November 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2023
London,UK

  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2022 At the Limits Ltd.
This site uses cookies More info